menu
    • menu

    Company profile for Shanghai Zhimeng Biopharma

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Shanghai Zhimeng Biopharma Inc. is a startup biotech founded in 2017 by seasoned pharmaceutical industry veterans. Located in the economy-vibrant and resource-rich Zhangjiang High-Tech Park of Shanghai, China, Zhimeng is developing medicines for the treatment of chronic hepatitis B (CHB) and severe neurological diseases with great unmet medical needs. Realizing the complexity of the pathogenesis of chronic hepatitis HBV in...
    Shanghai Zhimeng Biopharma Inc. is a startup biotech founded in 2017 by seasoned pharmaceutical industry veterans. Located in the economy-vibrant and resource-rich Zhangjiang High-Tech Park of Shanghai, China, Zhimeng is developing medicines for the treatment of chronic hepatitis B (CHB) and severe neurological diseases with great unmet medical needs. Realizing the complexity of the pathogenesis of chronic hepatitis HBV infection, Zhimeng has adopted a comprehensive approach to tackle the diseases by directly hitting the hepatitis B virus (HBV) with multiple pronged attacks, as well as restoring the host immune systems.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Shanghai Zhimeng BiopharmaChina Flag
    Country
    Country
    China
    Address
    Address
    1976 Gaoke Middle Road, Suite A-302. Pudong, Shanghai
    Telephone
    Telephone
    +86 21-50391670
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.core-biopharma.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Zhimeng Bio's Cb03-154 Hits First Patient Dose Milestone in ALS
    Zhimeng Bio's Cb03-154 Hits First Patient Dose Milestone in ALS

    31 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/zhimeng-biopharmas-investigational-drug-cb03-154-for-amyotrophic-lateral-sclerosis-has-achieved-the-first-patient-first-dose-milestone-in-the-phase-23-pivotal-clinical-trial-302599908.html

    PR NEWSWIRE
    31 Oct 2025
    Share Share
    Zhimeng's Drug Gets Approval for Phase 2 Epilepsy Trial in China
    Zhimeng's Drug Gets Approval for Phase 2 Epilepsy Trial in China

    11 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/zhimeng-biopharmas-investigational-drug-approved-to-initiate-phase-2-epilepsy-clinical-trial-in-china-302552191.html

    PR NEWSWIRE
    11 Sep 2025
    Share Share
    Zhimeng Biopharma's KCNQ2/3 Opener Approved for ALS Phase 2/3
    Zhimeng Biopharma's KCNQ2/3 Opener Approved for ALS Phase 2/3

    09 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/zhimeng-biopharmas-next-generation-kcnq23-potassium-channel-opener-receives-clinical-trial-approval-for-als-phase-23-study-302500086.html

    PR NEWSWIRE
    09 Jul 2025
    Share Share
    Zhimeng Biopharma CB03 Received Orphan Drug Designation from the US FDA
    Zhimeng Biopharma CB03 Received Orphan Drug Designation from the US FDA

    20 Oct 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/zhimeng-biopharma-cb03-received-orphan-drug-designation-from-the-us-fda---a-potassium-ion-channel-opener-for-amyotrophic-lateral-sclerosis-301962939.html

    PR NEWSWIRE
    20 Oct 2023
    Share Share
    Zhimeng Biopharma will report positive PIb trial results on its ZM-H1505R
    Zhimeng Biopharma will report positive PIb trial results on its ZM-H1505R

    14 Jun 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/zhimeng-biopharma-will-report-positive-phase-1b-trial-results-on-its-hbv-capsid-inhibitor-zm-h1505r-in-the-upcoming-international-liver-congress-301567111.html

    PRNEWSWIRE
    14 Jun 2022
    Share Share
    Zhimeng Biopharma Announces Dosing in CB03 in Phase I Clinical Trial
    Zhimeng Biopharma Announces Dosing in CB03 in Phase I Clinical Trial

    12 May 2022

    // ASIAONE

    https://www.asiaone.com/business/zhimeng-biopharma-announces-dosing-first-subject-its-novel-antiepileptic-drug-candidate

    ASIAONE
    12 May 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search